Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Terumo Debuts Cell-Based Heart Failure Therapy HeartSheet
Terumo said on May 30 that it has launched what it claims to be the world’s first regenerative medicine-based treatment for heart failure in Japan. HeartSheet, autologous skeletal myoblast sheets, is expected to treat some 20-30 patients a year, the…
To read the full story
Related Article
- Terumo Preparing to Launch HeartSheet; Sees Room for Improvements in Production and Quality Control
April 7, 2016
- Chuikyo Approves Listing of Temcell and HeartSheet, First Two Regenerative Medicine Products
November 19, 2015
- Japan Grants 1st Conditional Approval to Terumo’s HeartSheet
September 24, 2015
BUSINESS
- Kineret Could Bring Earlier Remission in Still’s Disease: Expert
September 8, 2026
- Shionogi’s Cefiderocol Approved in Australia
September 8, 2026
- Argenx Recalls 1 Lot of Vyvdura as Precaution over Foreign Matter
September 8, 2026
- Japan Ethical Drug Sales Rise 4.8% in July: Crecon
September 8, 2026
- Keytruda Holds Top Spot for 35th Straight Month in August: Encise
September 7, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…